You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
An α1-agonist; a potent orally active hypertensive.
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
References are publications that support the biological activity of the product.
Dabasaki et al (1992) Antihypotensive effects of M6434, an orally active alpha-1-adrenoceptor agonist in rats. Jpn.J.Pharmacol. 59 145 PMID: 1279249
Ohnish (1981) Pharmacological properties of 2-[(5-chloro-2-methoxyphenyl)azo]-1H-imidazole (M6434). Arzneimittelforschung 9 1425 PMID: 7197948
Tsuchid (1986) Effects of mido. on experimentally-induced postural hypotension in dogs. Arzneimittelforschung 12 1748 PMID: 2436631
View Related Products by Product Action
Keywords: M-6434, M-6434 supplier, An, a1-agonist;, a, potent, orally, active, hypertensive., Adrenergic, Alpha-1, Receptors, 0461, Tocris Bioscience
Citations for M-6434
Citations are publications that use Tocris products.
Currently there are no citations for M-6434.
Reviews for M-6434
There are currently no reviews for this product. Be the first to review M-6434 and earn rewards!
Have you used M-6434?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.